Scholar Rock, Inc.
10
2
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
20%
2 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Role: lead
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
Role: lead
A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults
Role: lead
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
Role: lead
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Role: lead
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Role: lead
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
Role: lead
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
Role: lead
Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
Role: collaborator
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Role: lead
All 10 trials loaded